Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Conatus Pharmaceuticals Inc (CNAT) USD0.0001

Sell:$0.34 Buy:$0.36 Change: $0.0361 (9.50%)
NASDAQ:0.91%
Market closed |  Prices as at close on 21 October 2019 | Switch to live prices |
Sell:$0.34
Buy:$0.36
Change: $0.0361 (9.50%)
Market closed |  Prices as at close on 21 October 2019 | Switch to live prices |
Sell:$0.34
Buy:$0.36
Change: $0.0361 (9.50%)
Market closed |  Prices as at close on 21 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.

Contact details

Address:
16745 W Bernardo Dr Ste 200
SAN DIEGO
92127-1906
United States
Telephone:
+1 (858) 3762600
Website:
https://www.conatuspharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CNAT
ISIN:
US20600T1088
Market cap:
$12.48 million
Shares in issue:
33.17 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • David Hale
    Independent Chairman of the Board
  • Steven Mento
    President, Chief Executive Officer, Director
  • Keith Marshall
    Chief Financial Officer, Principal Financial Officer, Chief Operating Officer, Executive Vice President
  • Alfred Spada
    Executive Vice President - Research & Development, Chief Scientific Officer
  • David Hagerty
    Executive Vice President, Clinical Development
  • Daniel Ripley
    Senior Vice President - Business Development, Program and Alliance Management
  • Edward Smith
    Senior Vice President - Regulatory Affairs and Quality Assurance
  • Michelle Vandertie
    Acting Principal Accounting Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.